US4292302A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polymeric diffusion matrix containing terbutaline
Assignee: Key Pharmaceuticals Inc
•
Filing: 1980-07-09
•
Granted: 1981-09-29
•
Expires: 2000-07-09
Abstract
Abstract There is disclosed a polymeric diffusion matrix for the sustained release of terbutaline by transdermal delivery to a patient wherein the matrix comprises a polar plasticizer, polyvinylalcohol, polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline.
Inventors
- 👤 Alec D. Keith
- 👤 Wallace Snipes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:01
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
78 words
A self-supporting polymeric diffusion matrix for the sustained release of terbutaline in order to transdermally deliver said terbutaline to a patient and provide said patient with a bronchodilator effect, said matrix comprising from about 2 to about 60% of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline to provide a sustained release of said terbutaline over a prolonged period.
Claim 2
Dependent Claim
78 words
A self-supporting polymeric diffusion matrix for the sustained release of terbutaline in order to transdermally deliver said terbutaline to a patient and provide said patient with a bronchodilator effect, said matrix comprising from about 2 to about 60% of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline to provide a sustained release of said terbutaline over a prolonged period.
Claim 3
Dependent Claim
13 words
The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is glycerol.
Claim 4
Dependent Claim
20 words
The polymeric diffusion matrix of claim 1 wherein said polyvinylalcohol has a molecular weight of about 50,000 to about 150,000.
Claim 5
Dependent Claim
20 words
The polymeric diffusion matrix of claim 1 wherein said polyvinylalcohol has a molecular weight of about 100,000 to about 150,000.
Claim 6
Dependent Claim
21 words
The polymeric diffusion matrix of claim 1 wherein said polyvinylpyrrolidone has a molecular weight of from about 15,000 to about 85,000.
Claim 7
Dependent Claim
20 words
The polymeric diffusion matrix of claim 1 wherein said polyvinylpyrrolidone has a molecular weight of about 20,000 to about 60,000.
Claim 8
Dependent Claim
26 words
The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is polyethylene glycol present in an amount of about 2 to about 15% by weight.
Claim 9
Dependent Claim
40 words
The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is a mixture of glycerol and polyethylene glycol wherein said polyethylene glycol is present in an amount by weight of from about 1 to 5 parts per weight glycerol.
Claim 10
Independent Claim
78 words
A method for the transdermal delivery of terbutaline to a patient to provide said patient with a bronchodilator effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline to provide a sustained release of said terbutaline over a prolonged period.
Claim 11
Independent Claim
78 words
A method for the transdermal delivery of terbutaline to a patient to provide said patient with a bronchodilator effect, comprising applying to said patient a self-supporting diffusion matrix comprising from about 2 to about 60% by weight of a polar plasticizer, from about 6 to about 20% by weight polyvinylalcohol, from about 2 to about 10% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of terbutaline to provide a sustained release of said terbutaline over a prolonged period.
Claim 12
Dependent Claim
26 words
The method of claim 9 wherein said terbutaline is present in an amount to provide sustained release of about 1 to about 20 mg per day.
References Cited (Backward Citations)
US2693438A
Cited
US2776924A
Cited
US2973300A
Cited
US3073742A
Cited
US3287222A
Cited
US3214338A
Cited
GB1108837A
Cited
CA930668A
Cited
US3598123A
Cited
US3608070A
Cited
BE764422A
Cited
US3731683A
Cited
US3742951A
Cited
US3742951B1
Cited
FR2224140A1
Cited
FR2224126A1
Cited
US3972995A
Cited
US4076798A
Cited
JPS5415117A
Cited
GB2021950A
Cited
FR2437830A1
Cited
US4210633A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-28 | 1985-03-30 | 1985-09-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-28 | 1989-03-30 | 1989-09-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-28 | 1993-03-30 | 1993-09-29 | $7700.00 | Window Closed / Lapsed |